A Study to Evaluate ALZT-OP1a in Subjects with Mild-to-Moderate Amyotrophic Lateral Sclerosis

Overview

About this study

The purposes of this study are to measure the impact of two doses of ALZT-OP1a (cromolyn) on neuro-inflammation by measuring plasma neuroinflammatory biomarkers over a 12-week treatment period, to evaluate the effects of ALZT-OP1a (cromolyn) on functional changes in subjects with mild-moderate stage ALS by using the ALS Functional Rating Scale-Revised (ALSFRS-R) to measure changes in function over a 12-week treatment period, to evaluate the safety of the ALZT-OP1a (cromolyn), and to determine the optimal dose selection of ALZT-OP1a (cromolyn) out of the two doses used in the study.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Male or female subjects, aged 18-75 years, both inclusive.
  • Must provide written informed consent before any study related procedures.
  • Capable of completing all trial related procedures, assessments and visits in the judgement of Investigator.
  • Familial or sporadic ALS diagnosed as possible, laboratory supported probable, probable, or definite as defined by revised El Escorial criteria.
  • Disease duration from ALS symptom onset of motor weakness ≤ 24 months.
  • ALSFRS-R total score ≥ 36 at screening visit.
  • ALSFRS-R Breathing sub-score should be ≥ 9 at the time of screening.
  • ALSFRS-R Bulbar sub-score should be ≥ 9 at the time of screening.
  • Peak inspiratory flow rate (PIFR) ≥ 100 L/minute.
  • Forced vital capacity (FVC) > 70% of predicted value.
  • If subject is receiving FDA-approved standard of care treatment, they must be on a stable dose for ≥30 days prior to signing informed consent.

Exclusion Criteria:

  • Subjects with bulbar-onset ALS
  • Any use of non-invasive ventilation (e.g., continuous positive airway pressure, non-invasive bi-level positive airway pressure or non-invasive volume ventilation) for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation.
  • Any other significant neurological disorder which can interfere with study assessments; e.g., significant cognitive impairment and/or clinical dementia.
  • Significant psychiatric illness like schizophrenia, bipolar disorder etc. Subjects with depression can be included, only if the depression has been stable and no episode of major depression has occurred in past one year.
  • Severe cardiac disease (e.g., QTc>500ms), Torsade de Pointes, evidence of significant heart failure (New York Heart Association [NYHA] Class 3 or greater, myocardial infarction or unstable angina in the 6 months prior to screening).
  • Any moderate-to-severe pulmonary disease or difficulty taking inhaled drugs.
  • Inability to tolerate the administration of an oral inhaled powder via dry powder inhaler (DPI).
  • Has taken any investigational study drug within 30 days or five half-lives of the drug, whichever is longer, prior to dosing.
  • Currently taking cromolyn, or has taken cromolyn, within the past 12 months.
  • Allergy to cromolyn or cromolyn products, such as Intal®, Nasalcrom®, Opticrom®, Gastrocrom®, etc.
  • Taking inhaled protein products on a chronic basis (such as insulin, parathyroid hormone [PTH], etc.).
  • Subjects who weigh 88 lb (40 kg) or less, or, body mass index (BMI) of 35.0 at screening.
  • Moderate-to-severe liver disease: aspartate aminotransferase (AST), alanine aminotransferase (ALT), or bilirubin concentrations > 3 times the upper limit of normal; patients with hepatic diseases such as hepatic cirrhosis, hepatic cancer and active hepatitis.
  • Moderate-to-severe renal disease: creatinine clearance < 45 mL/min/1.73 m^2 (by Cockcroft-Gault calculation).
  • Any clinically significant disorder or laboratory abnormality that, in the investigator's opinion, could interfere with the subject's participation in the study, place the subject at increased risk, or confound interpretation of the study results.
  • Pregnant or breast-feeding females or sexually active females with childbearing potential, if no adequate contraceptive measures are used.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Bjorn Oskarsson, M.D.

Contact us for the latest status

Contact information:

Pamela Desaro CCRP

Desaro.Pamela@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available